Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Accounts Payables (2016 - 2026)

Tenax Therapeutics' Accounts Payables history spans 6 years, with the latest figure at $611861.0 for Q4 2017.

  • On a quarterly basis, Accounts Payables fell 15.91% to $611861.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $611861.0, a 15.91% decrease, with the full-year FY2017 number at $611861.0, down 15.91% from a year prior.
  • Accounts Payables hit $611861.0 in Q4 2017 for Tenax Therapeutics, up from $579386.0 in the prior quarter.
  • Over the last five years, Accounts Payables for TENX hit a ceiling of $1.5 million in Q2 2016 and a floor of $434195.0 in Q2 2017.
  • Historically, Accounts Payables has averaged $942936.8 across 4 years, with a median of $890081.0 in 2013.
  • Biggest five-year swings in Accounts Payables: skyrocketed 80.02% in 2013 and later plummeted 71.46% in 2017.
  • Tracing TENX's Accounts Payables over 4 years: stood at $977162.0 in 2013, then decreased by 0.48% to $972483.0 in 2015, then dropped by 25.18% to $727599.0 in 2016, then decreased by 15.91% to $611861.0 in 2017.
  • Business Quant data shows Accounts Payables for TENX at $611861.0 in Q4 2017, $579386.0 in Q3 2017, and $434195.0 in Q2 2017.